These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 23150264)

  • 21. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.
    Turriziani O; Andreoni M; Antonelli G
    Clin Microbiol Infect; 2010 Oct; 16(10):1518-24. PubMed ID: 20673260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
    Chun TW; Fauci AS
    AIDS; 2012 Jun; 26(10):1261-8. PubMed ID: 22472858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
    Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
    J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers to HIV Cure.
    Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
    HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
    Pomerantz RJ
    Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Underlying mechanisms of HIV-1 latency.
    Romani B; Allahbakhshi E
    Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.
    Sánchez-Duffhues G; Vo MQ; Pérez M; Calzado MA; Moreno S; Appendino G; Muñoz E
    Curr Drug Targets; 2011 Mar; 12(3):348-56. PubMed ID: 20955147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 dynamics in vivo: implications for therapy.
    Simon V; Ho DD
    Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can HIV infection be eradicated through use of potent antiviral agents?
    Josefsson L; Dahl V; Palmer S
    Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
    Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
    Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The search for a cure for persistent HIV reservoirs.
    Lafeuillade A; Stevenson M
    AIDS Rev; 2011; 13(2):63-6. PubMed ID: 21587339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
    Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
    Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evolution and Diversity of HIV-1].
    Metzner KJ
    Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetics of HIV infection: promising research areas and implications for therapy.
    Ay E; Banati F; Mezei M; Bakos A; Niller HH; Buzás K; Minarovits J
    AIDS Rev; 2013; 15(3):181-8. PubMed ID: 24002202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antiretroviral resistance in human immunodeficiency virus infection].
    Afani S A; Gallardo O AM
    Rev Chilena Infectol; 2011 Oct; 28(5):461-9. PubMed ID: 22051623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV reservoirs, latency, and reactivation: prospects for eradication.
    Dahl V; Josefsson L; Palmer S
    Antiviral Res; 2010 Jan; 85(1):286-94. PubMed ID: 19808057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
    Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
    Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.